The cisplatin content could promote radiotherapy-induced tumor cell ICD through photoelectric mechanism to facilitate T cell activation, while the aptamer components could further self-assemble into PD-L1-PD-1 bispecific T cell engagers in the TME in an in-situ manner to enable direct binding of PD-1-expressing cytotoxic T cells onto PD-L1-upregulated RT-exposed tumor cells, thus kickstarting the post-RT cancer-immunity cycle while antagonizing PD-L1 immune checkpoint for improving the T cell-mediated antitumor responses. Here, CD274 is linked to neoplasm.